March 24, 2025
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited
23andMe files for bankruptcy as CEO Anne Wojcicki steps down to become bidder
Bankruptcy, CEO, Anne, Customer
Unitys eye treatment fails to match Eylea, though analysts still see a path forward
analysts, Eylea, match Eylea, Macular edema due to diabetes mellitus
Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking the big next step after AlphaFold 3
Neo-1, Study models, molecular glues
AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure
Investments, China, Evaluation procedure